Movement Disorders

The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.

Michela Leocadi, PhD, research fellow at UCL Queen Square Institute of Neurology, discussed new longitudinal data showing early functional connectivity changes in HD gene carriers years before clinical motor diagnosis.

In a phase 4 randomized controlled trial, opicapone failed to demonstrate statistical superiority over placebo for reducing fluctuation-related pain in patients living with Parkinson disease.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.

A newly launched global phase 3 trial will compare once-daily trientine to D-penicillamine as a first-line treatment for patients with Wilson disease, a rare genetic disorder.

Newly published KINECT-PRO data showed that valbenazine boosted quality of life and function while reducing movement severity, with remission for many patients with tardive dyskinesia by 24 weeks.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 4, 2026.

Olfactory dysfunction, dysautonomia, mood disturbance, and motor deficits disproportionate to dopaminergic denervation may serve as markers of amyloid-β positivity in newly diagnosed Parkinson disease.

Catch up on any of the neurology headlines you may have missed in August 2026, compiled into 1 place by the NeurologyLive® team.

Newly published longitudinal fMRI data revealed that presymptom Huntington gene carriers had striatal network shifts up to 20 years early, potentially sharpening targets for studies in the future.

uniQure submitted a BLA to FDA and an MAA to the UK's MHRA for ifezuntirgene inilparvovec, based on 3-year phase 1/2 data showing slowed Huntington disease progression.

The European Commission approved modified-release carbidopa/levodopa capsules, already available in the US as Crexont, for adults with moderate to severe motor fluctuations.

An analysis of more than 311,000 UK Biobank participants identified 13 pairs and 14 triplets of risk factors with significant additive interactions for late-onset Parkinson disease, with several potentially modifiable factors emerging as targets for prevention.

Lucy Morse, MD, a movement disorders specialist at Northwestern Medicine, discussed the push toward a biological definition for Parkinson disease, newly approved therapies, and why she believes referrals shouldn't wait.

Findings from a phase 1 study showed that bilateral putaminal delivery of AAV2-GDNF using convection-enhanced delivery was well tolerated over 5 years, although exploratory clinical measures did not demonstrate significant improvements from baseline.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Huntington disease!

Full results from the phase 3 TEMPO-2 trial, published in Lancet Neurology, showed that flexible-dose tavapadon significantly improved motor symptoms and daily function in people with early Parkinson disease.

A recently published phase 2 trial showed that CBD/THC cannabis oil failed to ease chronic pain or nonmotor symptoms versus placebo among patients with Parkinson disease.

David Stamler, MD, Chief Executive Officer of Alterity Therapeutics, discusses the FDA's alignment on the pivotal Phase 3 program for ATH434 in multiple system atrophy and what a successful trial could mean for a disease with no approved disease-modifying therapies.

Teva Pharmaceuticals' ecopipam receives priority review by the FDA, supported by studies showing sustained tic control among pediatric patients with Tourette syndrome.

Horacio Kaufmann, MD, Director of the Dysautonomia Center at NYU Langone, discusses the prospective validation of prodromal MSA criteria, how olfactory testing can sharpen specificity, and how close the field is to biomarker-driven early diagnosis.

Investigators independently tracked the 6 patients treated in a Parkinson disease gene therapy trial that was abandoned mid-study after its sponsor became insolvent, finding a reassuring safety profile and mixed signals of motor benefit through up to 3 years.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending August 7, 2026.

Topline findings from the Phase 2 SUNRISE-PD study showed statistically significant improvements in clinical measures, inflammatory biomarkers, and exploratory neurodegeneration markers among patients with early Parkinson disease treated with bezisterim.